Dupilumab and Crisaborole for Atopic Dermatitis: Effectiveness and Value

Draft Voting Questions for May 25, 2017 Public Meeting

These questions are intended for the deliberation of the Midwest CEPAC voting body at the public meeting.

1) In patients with mild to moderate atopic dermatitis, is the evidence adequate to demonstrate that the net health benefit of treatment with crisaborole is greater than that of treatment with topical corticosteroids or topical calcineurin inhibitors?
   Yes  No

2) In adults with moderate to severe atopic dermatitis who have failed topical therapy, is the evidence adequate to demonstrate that treatment with dupilumab provides additional net health benefits beyond continued non-pharmacologic treatments such as emollients?
   Yes  No

3) In adults with moderate to severe atopic dermatitis who have failed topical therapy, is the evidence adequate to demonstrate that the net health benefit of treatment with dupilumab is greater than that of treatment with cyclosporine?
   Yes  No

The Council will be asked to vote on other benefits, disadvantages, and contextual considerations with regard to treatment of adults with moderate to severe atopic dermatitis with dupilumab. Voting will be translated into a single cost per QALY threshold price between $50,000 per QALY and $150,000 per QALY. This will be used to determine the ICER value-based price benchmark for dupilumab as well as the judgment of whether dupilumab provides low, intermediate, or high long-term value for money. Refinement of this approach is awaiting the conclusion of a public comment period; the outline for this approach is available here.